Admin_Adham
March 27 (Reuters) - Eli Lilly said on Friday that its eczema drug showed durable results in a late-stage post-marketing study, such as relief from persistent itch for up to four years in patients with the skin condition.
Here are more details:
- A once-monthly injection of the drug, Ebglyss - approved in the United States in 2024 - showed durable response in patients with moderate-to-severe atopic dermatitis, which causes intense itching.
- The injectable treatment is approved for adults and children 12 years and older with moderate-to-severe eczema who cannot use topical therapies.
- In the study, majority of patients achieved near-complete skin clearance and itch relief with up to four years of continuous treatment, Lilly said.
- Ebglyss' safety in the first year of the study was consistent with its known profile, regardless of dosing frequency, and no new safety issues were observed, the company said.
- The study will continue for an additional year of treatment.
- Lilly last year reported results from another trial showing Ebglyss provided a durable response when dosed every four or eight weeks. The drugmaker said it has submitted the data to the U.S. Food and Drug Administration for a potential label update.
(Reporting by Sneha S K in Bengaluru; Editing by Diti Pujara)
